ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
61,489.65
0.98%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCCP)

  7. Cyclacel Pharmaceuticals Inc (CYCCP) News

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYCCP
DateTimeSourceHeadlineSymbolCompany
26/06/202414:15GlobeNewswire Inc.Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
04/06/202413:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/06/202413:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
17/05/202414:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202422:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202421:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/05/202421:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202414:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202402:56Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202402:53Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202402:52Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/05/202422:26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
02/05/202421:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202418:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202412:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/04/202414:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
19/03/202420:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/03/202420:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/03/202414:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/03/202414:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
20/02/202414:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202421:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202421:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202415:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/02/202420:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/02/202422:03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
31/01/202421:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCCP

Your Recent History

BOV
BNBR3M
BANCO NORDESTE ON
TG
A19R7J
Societe Generale
BIT
UC7A8K
Unicredit Bank
TG
A1ZWZN
Statoil ASA
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved